Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Dec 29, 2022 4:44pm
77 Views
Post# 35196027

RE:RE:RE:Last day for tax-loss selling is today!

RE:RE:RE:Last day for tax-loss selling is today!
Lol, everybody's talked to Graeme. And then they talk to me. From what I hear, he's only got 5-word cliches for answers about the deal, and nothing about agreement details.  It's not his fault. There's no way that DrDR would give him any substantive talking points. 
 
I don't dispute that there is value to Hunter syndrome. Q-Sphera could also be a differentiator for it.
 
But Bioasis, in the Chiesi deal, valued a single LSD at less than $750,000 up front and less than $35 million in milestone payments. 
 
And Hunter syndrome is touted as the lead program? Come on!
 
If Bioasis (Graeme, DrDR, pof and fuzzy) think that there's something special about metered (Q-Sphera) delivery, great, but the LSDs, metered or not, aren't worth anything compared to brain tumours, Parkinson's, Alzheimer's, MS, neuroinflammation and a host of other targets that Dr. Deborah Rathjen, Graeme, and Midatech are not discussing with anybody for any reason.
 
Hunter syndrome. Hoo-rah! You will learn that either Hunter syndrome is worth a lot or that DrDR completely failed to get a proper deal with Chiesi. Can't be both.
 
jd
<< Previous
Bullboard Posts
Next >>